You are here
P&T® Journal contents for December 2010
Letter to the Editor
Part 3: Challenges Facing Health Care Plans in Implementing Coverage Policies for Pharmacogenomic and Genetic Testing
The final part of this series covers the usefulness of genetic testing, trends in insurance underwriting, and the anticipated pipeline for new biologics.
Efficacy and Safety of a Lower-Dose Valganciclovir (Valcyte) Regimen for Cytomegalovirus Prophylaxis In Kidney and Pancreas Transplant Recipients
Using a lower dose of valganciclovir, at 450 mg daily for six months instead of the recommended 900-mg daily dose, can be efficacious for patients and less expensive for hospitals. The result: reduced drug costs and fewer cases of leukopenia.
A Literature Review from a Global Health Systems Perspective
Although the burden of psoriatic arthritis has been described extensively in the literature, the burden of illness associated with PsA has not been as well qualified. The authors discuss the substantial economic and quality-of-life costs to patients and society.
Topics include onabotulinumtoxinA (Botox) for migraine; dabigatran (Pradaxa) for reducing stroke and embolism risk; and lurasidone (Latuda) for schizophrenia.
Selected sessions focused on incobotulinumtoxinA (Xeomin) for focal dystonias.